| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Oncternal Therapeutics (NASDAQ:ONCT) reported its Q4 earnings results on Thursday, March 7, 2024 at 04:01 PM.
Here's what investors need to know about the announcement.
Oncternal Therapeutics missed estimated earnings by -1.0%, reporting an EPS of $-3.11 versus an estimate of $-3.07.
Revenue was up $126 thousand from the same period last year.
Last quarter the company missed on EPS by $0.6 which was followed by a 3.0% drop in the share price the next day.
Here's a look at Oncternal Therapeutics's past performance:
| Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|
| EPS Estimate | -2.8 | -3.2 | -4 | -4.2 |
| EPS Actual | -3.4 | -3 | -4 | -4 |
| Revenue Estimate | 120K | 200K | 170K | 330K |
| Revenue Actual | 179K | 106K | 203K | 171K |
To track all earnings releases for Oncternal Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: ONCT
